Antimicrobial agents and compositions related to platelet factor 4

Recombinant platelet factor 4 compositions, especially in dimeric and monomeric forms, effectively combat antibiotic-resistant bacteria by enhancing phagocytosis and bacterial clearance, offering a promising treatment for infections like those caused by Staphylococcus aureus and Klebsiella pneumoniae.

WO2026236412A1PCT designated stage Publication Date: 2026-11-12THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIV OF ARIZONA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/026975
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-06
Filing Date
2026-05-06
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

The rise of antibiotic-resistant bacteria poses a significant challenge in treating infectious diseases, particularly those caused by Gram-negative bacteria, necessitating the development of new antimicrobial agents.

Method used

Compositions comprising recombinant platelet factor 4 (rPF4) in dimeric and monomeric aggregation states, optionally pegylated with a polyethylene glycol chain, are used to enhance phagocytosis and combat antibiotic-resistant bacteria, potentially combined with antibiotics or glucocorticoids for synergistic effects.

Benefits of technology

The rPF4 compositions demonstrate enhanced phagocytosis of bacteria, improving bacterial clearance and survival rates in animal models, particularly against antibiotic-resistant strains like Staphylococcus aureus and Klebsiella pneumoniae, with reduced immunogenicity and improved safety through pegylation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026026975_12112026_PF_FP_ABST
    Figure US2026026975_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The present disclosure relates to compositions comprising monomers or dimers of platelet factor 4 (PF4) or a variant thereof. In some aspects, the antimicrobial composition does not comprise trimers or tetramers of PF4. In certain embodiments, the antimicrobial composition comprises recombinant PF4 or a variant thereof. In particular embodiments, the PF4 in the antimicrobial compositions is monopegylated. The compositions are useful for treating a microbial infection. Also disclosed are methods for monospecific pegylation of PF4 and a method of treating or reducing the severity of a bacterial infection in a subject using an antimicrobial composition described herein.
Need to check novelty before this filing date? Find Prior Art

Description

Attorney Docket No. 11157.215W0-PCTANTIMICROBIAL AGENTS AND COMPOSITIONS RELATED TO PLATELET FACTOR 4RELATED APPLICATIONS

[0001] This application claims priority to and the benefit of U.S. provisional patent application 63 / 801,119, filed May 6, 2025, titled “ANTIMICROBIAL AGENTS AND COMPOSITIONS RELATED TO PLATELET FACTOR 4,” the entirety of the disclosure of which is hereby incorporated by this reference.SEQUENCE LISTING

[0002] In accordance with 37 C.F.R. § 1.831, the present specification makes reference to a Sequence Listing submitted electronically in the form of an XML file (entitled “11157-215SeqList.xml”, created on May 4, 2026, 6,813 bytes in size). The entire contents of the Sequence Listing are herein incorporated by reference in their entirety, with the intention that, upon publication (including issuance), this incorporated Sequence Listing will be inserted in the published document immediately before the claims.STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

[0003] This invention was made with government support under R01 HL063199, awarded by the National Institutes of Health. The government has certain rights in the invention.FIELD OF THE INVENTION

[0004] The invention relates to antimicrobial compositions effective even on antibioticresistant bacterial. The compositions comprise platelet factor 4 (PF4), including its variants and fragments thereof, in a dimeric aggregation state and their methods of use.BACKGROUND OF THE INVENTION

[0005] Since Sir Alexander Fleming’ s discovery of penicillin, the first modern-day antibiotics, in 1928, bacterial infections have again become possibly untreatable due to the rise of antibiotic resistance. While overuse and misuse of antibiotics attribute to the antibiotic resistance crisis, the prevailing natural phenomenon of survival means that bacteria will ultimately develop resistance to modern-day antibiotics even with responsible use. Treatment of infectious diseases now is significantly threatened by antibiotic-resistant bacteria, which poses a globalAttorney Docket No. 11157.215W0-PCTchallenge that impacts both human and animal health. A particularly serious concern is the rise of Gram-negative bacteria developing resistance to nearly all available antibiotics, leading to a state known as multidrug resistance. The global challenges posed by these drug-resistant bacteria have prompted efforts to seek new traditional antibiotics as well as non-traditional treatment options. Accordingly, there is a great need to discover and develop new antimicrobial agents.

[0006] Platelet factor 4 (PF4, UniProtKB-P02776), which is one of the most abundant cationic proteins secreted from a-granules of activated platelets, has been deemed a target for developing novel antimicrobial agents. Based on its structure, PF4 was assigned to the CXC family of chemokines and has been shown to exert numerous effects on myeloid leukocytes. Accordingly, PF4 may modulate leukocyte activities.SUMMARY OF THE INVENTION

[0007] Compositions comprising platelet factor 4 (PF4) and / or variant thereof in dimeric and monomeric aggregation states are disclosed. In one aspect, the composition comprises a recombinant PF4 (rPF4). In some embodiments, wherein the composition does not comprise a trimer or a tetramer of PF4 or variant thereof. In some implementations, the compositions are antimicrobial compositions. In some implementations, pharmaceutical compositions for use in the treatment of a microbial infection are also disclosed. In some aspects, the microbial infection is caused by antibiotic-resistant bacteria.

[0008] The rPF4 or variant thereof in the composition has an aggregation state comprising at least 60% dimers, at least 70%, or at least 75% of the PF4 is in the dimeric aggregation state. In certain embodiments, the rPF4 or variant thereof in the composition has an aggregation state comprising at least 10% monomers and at least 70% dimers, for example, about 20% monomers and 80% dimers. In some aspects, the composition consists essentially of platelet factor 4 (PF4) and / or variant thereof in dimeric and monomeric aggregation states.

[0009] In particular embodiments, the rPF4 variant has a binding site for CR3 aMI-domain having an amino acid sequence selected from: APLYKKIIKKLLXiS (Xi is not E or wherein Xi is R or a conservative substitution thereof, SEQ ID NO: 3) and CVKX2X3SQVRPRHITS (X2 is not T or is R or a conservative substitution thereof and / or X3 is not T or is R or a conservative substitution thereof, SEQ ID NO: 2). In some embodiments, rPF4 or variant thereof are pegylated with a polyethylene glycol (PEG) chain of 10 kDa or less in weight at its N-terminus. In certain embodiments, the PEG chain is a methoxy PEG propionaldehyde (mPEG). In some implementations, the PEG chain is 5 kDa.Attorney Docket No. 11157.215W0-PCT

[0010] In one aspect, the composition comprises mono-pegylated PF4, mono-pegylated PF4 variant, or mono-pegylated PF4 fragment. In such a composition, the N-terminal of the PF4, the PF4 variant, or the PF4 fragment is pegylated with a PEG chain, for example, mPEG of 10 EDa or less in weight. In particular embodiments, the molecular weight of the PEG chain is 5 EDa or less. In some aspects, the PF4 or the PF4 variant is encoded by a DNA sequence having at least 90%, at least 95%, or at least 98%, or at least 99% sequence identity to SEQ ID NO: 1. In certain embodiments, the PF4 variant comprising an amino acid sequence as a binding site for CR3 aMI-domain selected from: APLYKKIIKKLLXiS (Xi is not E or wherein Xi is R or a conservative substitution thereof, SEQ ID NO: 3) and CVKX2X3SQVRPRHITS (X2 is not T or is R or a conservative substitution thereof and / or X3 is not T or is R or a conservative substitution thereof, SEQ ID NO: 2). Accordingly, mono-pegylated PF4, mono-pegylated PF4 variant, or mono-pegylated PF4 fragment are disclosed herein.

[0011] In some implementations, the monomer and / or dimer of PF4 or variant thereof is encoded by a DNA sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 1. In some implementations, the variant of PF4 comprising an amino acid sequence as a binding site for CR3 aMI-domain selected from: APLYKKIIKKLLXiS (Xi is not E or wherein Xi is R or a conservative substitution thereof, SEQ ID NO: 2) and CVKX2X3SQVRPRHITS (X2 is not T or is R or a conservative substitution thereof and / or X3 is not T or is R or a conservative substitution thereof, SEQ ID NO: 3). In certain embodiments of the composition, the monomer or the dimer of PF4 is pegylated at the N-terminal of the PF4 with a PEG chain of less than 10 EDa or less than 5 EDa in weight. In particular embodiments, the monomer and / or dimer of PF4 or a variant thereof is pegylated with mPEG.

[0012] Kits for clearance of a bacterial infection and for management of sepsis are also disclosed. The kit clearance of a bacterial infection comprises a composition described above and at least one of additional active ingredient selected from an antibiotic and a non-antibiotic antibacterial substance. The kit for management of sepsis comprises a composition described above and a glucocorticoid.

[0013] Methods of treating a bacterial infection or reducing its severity in a subject are further disclosed. The methods comprise administering a composition described above to the subject. In some aspects, the bacterial infection is caused by antibiotic-resistant bacteria. The methods further comprise administering to the subject an antibiotic or a non-antibiotic antibacterial substance. In some implementations of reducing the severity of a bacterial infection, theAttorney Docket No. 11157.215W0-PCTmethod further comprises administering to the subject a glucocorticoid. In such implementations, the bacterial infection has resulted in sepsis in the subject.

[0014] A method for monospecific pegylation of PF4 is disclosed. The method comprises providing recombinant PF4 (rPF4) and a PEG chain at a molar ratio of at no more than 10 moles of the PEG chain to 1 mole of rPF4; combining the rPF4 and the PEG chain in a buffer with a pH of no higher than 6.0 to produce a pegylation reaction mixture; allowing the rPF4 and PEG chain to react in the buffer for 18-36 hours; and isolating monopegylated rPF4 from the pegylation reaction mixture. The PEG chain has a molecular weight of less than 10 kDa or less than 5 kDa. In some implementations, the rPF4 and PEG chain are provided at a molar ratio of 3-10 moles of the PEG chain to 1 mole of rPF4, 3-5 moles of the PEG chain to 1 mole of rPF4, or about 4 moles of the PEG chain to 1 mole of rPF4. In some embodiments, the rPF4 is pegylated using aldehyde chemistry in a buffer comprising a sodium borohydride, for example, NaCNBH?. In some aspects, the PEG chain is a mPEG.

[0015] Also described are the use of PF4 and / or variant thereof in the dimeric aggregation state in the manufacture of an antimicrobial medicament. In another aspect, the use of PF4 and / or variant thereof in dimeric and monomeric aggregation states in the manufacture of an antimicrobial medicament is described.

[0016] The foregoing and other aspects, features, and advantages will be apparent from the DESCRIPTION and DRAWINGS, and from the CLAIMS.BRIEF DESCRIPTION OF THE DRAWINGS

[0017] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.

[0018] FIGs. 1 A-1C depict, in accordance with certain embodiments, SDS-PAGE and Western blotting of recombinant (rPF4) and native PF4 (PF4-N) isolated from platelets. Recombinant PF4 (rPF4) generated using a pET-15b plasmid migrates as a single band in the 4-20% SDS-polyacrylamide TRIS-glycine gel with a molecular weight of ~12 kDa (FIG. 1A). This molecular weight was confirmed by Western blotting with anti-PF4 polyclonal antibodies (FIG.1C). As small proteins exhibit atypical behavior in the TRIS-glycine buffer system, rPF4 was also analyzed using a TRIS-tricine buffer system amenable to small proteins and peptides, which show a molecular weight ~10 kDa (FIG. IB), which is still higher than a theoretical 7.8 kDa expected for a PF4 monomer.Attorney Docket No. 11157.215W0-PCT

[0019] FIG. 2 depicts, in accordance with certain embodiments, aggregation states of rPF4 and PF4-N using size-exclusion chromatography. The first (top) panel shows the elution profile of the molecular weight markers and their corresponding molecular weights. The second panel shows the elution profile of a rPF4 sample, which is a mixture of 80% dimers and 20% monomers. The third and fourth (bottom) panels show the elution profile of two preparations of native PF4 (PF4-N-1 and PF4-N2). Both preparations of PF4-N contain trimers and tetramers.

[0020] FIGs. 3A-3D compare the activity of rPF4 (FIG. 3A) with that of two preparations of PF4-N (FIGs 3B and 3C) in a flow-cytometry-based phagocytic assay using pHrodo-labeled Staphylococcus aureus bioparticles and a mouse macrophage cell line IC-21. As shown in FIG.3D, PF4-N exhibited a markedly lower phagocytosis-promoting activity of pHrodo-labeled S. aureus particles by macrophages than rPF4.

[0021] FIGs. 4A-4C depict, in accordance with certain embodiments, rPF4 promotes S. aureus clearance and improves survival in a mouse peritonitis model. FIG. 4B is a graphical presentation of the colony-forming units (CFU) recovered from the lavage of mice that were inoculated with S. aureus alone (1 x 107colony -forming units, CFU) or with a combination of endotoxin-free recombinant PF4 (20 pg) and S. aureus (1 x 107CFU). FIG. 4A shows two exemplary agar plates. FIG. 4C: Kaplan-Meier analysis of mice (n=13 mice per group) after IP injection of S. aureus (5 x 108CFU) without or with 13 pg / mouse (0.6 mg / kg) of rPF4 reveals a significant survival benefit for PF4-injected mice. There is a statistically significant difference between survival curves, p <0.001.

[0022] FIGs. 5A and 5B depict, in accordance with certain embodiments, that rPF4 enhances phagocytosis of K. pneumoniae by macrophages. FIG. 5A: Effect of rPF4 on phagocytosis of K. pneumoniae by suspended IC-21 macrophages. Cells were incubated with fluorescein-labeled, heat-inactivated K. pneumoniae (ATCC13883; capsule type K3) pretreated with 50 pg / ml rPF4 for 30 minutes at 37°C. Phagocytosis was measured using flow cytometry. Shown are representative histograms from eight independent experiments. FIG. 5B: Quantification of the effect of different concentrations of rPF4 on phagocytosis of K. pneumoniae by suspended mouse IC-21 macrophages based on flow cytometry results. MFI, mean fluorescence intensity. Data are presented as the mean fold difference in MFI ± standard deviation from 3-8 independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001, ns, nonsignificant.

[0023] FIGs. 6A-6E depict, in accordance with certain embodiments, that rPF4 enhances the clearance of high-virulence K. pneumoniae, reduces tissue damage, and improves survival rates in a mouse sepsis model. FIG. 6A: Bacterial loads in peritoneal lavage, blood, lung, and liverAttorney Docket No. 11157.215W0-PCTwere collected 24 hours after infection of C57BL / 6 mice with K. pneumoniae (104CFU). Data show the fold change in bacterial load (CFU / ml) between rPF4-treated and untreated mice, expressed as mean ± S.D. from 6 mice per group. FIG. 6B: H&E-stained sections were collected from the lungs of control (K. pneumonia only) and rPF4-treated mice 24 hours after infection. FIG. 6C: Representative images of liver lobes from healthy, infected with K. pneumoniae, and rPF4-treated mice 24 hours after infection. FIG. 7D: H&E-stained liver sections. FIG. 6E: Kaplan-Meier survival curves of mice (n = 6-10 per group) following intraperitoneal infection with high virulence K. pneumoniae (3 x 104CFU) with or without rPF4 treatment at different concentrations.

[0024] FIGs. 7A and 7B depict, in accordance with certain embodiments, a comparison of the rPF4 produced according to the methods described herein (rdPF4) and a commercially available rPF4. FIG. 7A: Size-exclusion chromatography of rdPF4 (second panel) and recombinant PF4 obtained from BioLegend (third panel). The elution profile of the molecular weight markers and their corresponding molecular weights are shown in the top panel. FIG.7B: Phagocytosis-promoting activity of rdPF4 and recombinant PF4 obtained from BioLegend determined by flow-cytometry using pHrodo-labeled S. aureus bioparticles and mouse IC-21 macrophages.

[0025] FIG. 8 depicts, in accordance with certain embodiments, rPF4 does not have a cytotoxic effect on mammalian cells. The figure is representative of three experiments. The difference between LL-37 and rPF4 for each concentration is statistically significant. ***p< 0.001.

[0026] FIGs. 9A-9C depict, in accordance with certain embodiments, PEGylation of rPF4 using methoxy-PEG-lOK. FIG. 9A: SDS-PAGE analysis of the samples from the PEGylation mixture obtained from the reaction at various times. M, molecular weight markers. FIG. 9B: Separation of the 6-hour mixture using size-exclusion chromatography. Upper panel, molecular weight markers; middle panel, initial rPF4; bottom panel, fractions separated by size-exclusion chromatography. Material in peak 2 corresponds to initial rPF4, and material in peak 1 corresponds to PEGylated products. FIG. 9C: Determination of the activity of PEGylated material using a phagocytic assay with pHrodo S. aureus bioparticles and IC21 macrophages.

[0027] FIGs. 10A-10D in accordance with certain embodiments, PEGylation of rPF4 using methoxy -PEG-5K. FIG. 10A: SDS-PAGE analysis of the samples from the PEGylation mixture obtained from the reaction at various times. M, molecular weight markers. FIG. 10B: Separation of the 22-hour mixture using cation-exchange chromatography. FIG. 10C: SDS-PAGE of fractions separated by cation-exchange chromatography. Material in fraction # 4Attorney Docket No. 11157.215W0-PCTcorresponds to mono-PEGylated PF4. FIG. 10D: Determination of the activity of PEGylated material using a phagocytic assay with pHrodo S. aureus bioparticles and IC21 macrophages.DETAILED DESCRIPTION OF THE INVENTION

[0028] Detailed aspects and applications of the invention are described below in the drawings and detailed description of the invention. Unless specifically noted, it is intended that the words and phrases in the specification and the claims be given their plain, ordinary, and accustomed meaning to those of ordinary skill in the applicable arts.

[0029] In the following description, and for the purposes of explanation, numerous specific details are set forth in order to provide a thorough understanding of the various aspects of the invention. It will be understood, however, by those skilled in the relevant arts, that the present invention may be practiced without these specific details. It should be noted that there are many different and alternative configurations, devices and technologies to which the disclosed inventions may be applied. The full scope of the inventions is not limited to the examples that are described below.

[0030] The singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a step” includes reference to one or more of such steps.

[0031] As used herein, the term “antibiotics” or “antibiotic compound” refers to a naturally produced antibacterial substance. For example, the term includes penicillin, tetracycline, erythromycin, methicillin, gentamicin, vancomycin, imipenem, ceftazidime, ceftriaxone, ampicillin, levofloxacin, linezolid, daptomycin, amphotericin B, cephalosporin, ceftaroline, azithromycin, and meropenem.

[0032] As used herein, the term “non-antibiotic antibacterial substance” includes synthetic antibacterial substances, for example, sulfonamides or antiseptics.

[0033] As used herein, the term “native form” of a protein refers to the functional form of the protein that occurs naturally in a living organism. Thus, the terms “native form of PF4” and “native PF4” refer to PF4 secreted by platelets. PF4 isolated from platelets are predominantly in the tetrameric aggregation state.

[0034] As used herein, a nucleic acid sequence is a “variant” of another nucleic acid sequence if it retains the function of the nucleic acid sequence (e.g., encoding a gene or cDNA sequence), but:(1) lacks 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides of the nucleotides of such nucleic acid sequence, orAttorney Docket No. 11157.215W0-PCT(2) lacks 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 of the 103' terminal nucleotides of nucleic acid sequence, or(3) lacks 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 of the 10 5' terminal nucleotides of such nucleic acid sequence, or(4) has a sequence that differs from that of such nucleic acid sequence in having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more than 10 additional nucleotides, or(5) has a sequence that differs from that of such nucleic acid sequence in having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more than 10 substitution nucleotides in lieu of the nucleotides present in such primer or probe, or(6) possesses a combination of such (l)-(5).

[0035] In some aspects, the nucleic acid sequence variant has no more than 6 substitutions, deletions, or additions.

[0036] As used herein, an amino acid sequence encodes a “variant” of protein if it retains the function of the whole protein or the function of at least one domain of the protein, but:(1) lacks 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 residues of the amino acid residues of such protein or of the amino acid residues of a domain of the protein, or(2) lacks a domain of such a protein, or(3) has an amino acid sequence that differs from that of such protein in having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more than 10 substitutions in lieu of the residues present in such protein or present in a domain of the protein, or(4) has a sequence that differs from that of such protein in having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more than 10 additional residues present in such protein or present in a domain of the protein, or(5) has a sequence that differs from that of such primer or probe in having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more than 10 substitution nucleotides in lieu of the nucleotides present in such primer or probe, or(6) possesses a combination of such (l)-(5).

[0037] In some aspects, the protein variant has no more than 3 substitutions, deletions, or additions. In some implementations, the protein variant has 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more than 10 conservative substitutions. As used herein, the term “conservative substitution” refers to an amino acid replacement that has similar biochemical properties (for example, charge, hydrophobicity, and size). In some instances, substitution may be one in which an amino acid residue is replaced with another amino acid residue having a similar side chain. Exemplary conservative substitutions are set out in Tables 1 and 2.Attorney Docket No. 11157.215W0-PCTTable 1.Side Chain Characteristic Amino Acid AliphaticNon-polar G, A, PI, L, V Polar, uncharged C, S, T, M N, Q Polar, charged D, EK, R Aromatic H, F, W, Y Non-polar (hydrophobic)Aliphatic A, L, I, V, P Aromatic F, W Sulfur-containing M Borderline G Uncharged-polarHydroxyl S, T, Y Amides N, Q Sulfhydryl C Borderline G Positively charged (basic) K, R, HNegatively charged (acidic) D, ETable 2.Original Residue Substitutions Alanine (A) V, L, IArginine (R) L, Q, N Asparagine (N) Q, H, K, R Aspartic Acid (D) ECysteine (C) SGlutamine (Q) NGlutamic Acid (E) DHistidine (H) N, Q, K, R Isoleucine (I) L, V, M, A, F Leucine (L) I, V, M, A, F Lysine (K) R, Q, N Methionine (M) L, F, I Phenylalanine (F) L, V, I, AProline (P) GSerine (S) TThreonine (T) STryptophan (W) Y, FTyrosine (Y) W, F, T, SValine (V) I, L, M, F, AAttorney Docket No. 11157.215W0-PCT

[0038] PF 4 induces leukocyte responses through the integrin CR3 (also known as Mac-1, aMp2, and CDllb / CD18). CR3 is a phagocytic receptor, and its aMI-domain is the ligandbinding domain of this receptor. Human neutrophils, monocytes, U937 monocytic and model HEK293 cells expressing CR3 strongly adhered to immobilized PF4 in a CR3-dependent manner. PF4 also induced the CR3-dependent migration of human neutrophils and monocyte / macrophages. Importantly, coating bacteria (for example, Escherichia coli and Staphylococcus aureus) or latex beads with PF4 enhanced their phagocytosis by macrophages by approximate 4 folds. This process was blocked by different CR3 antagonists. Furthermore, PF4 potentiated phagocytosis by wild-type, but not CR3-deficient macrophages. Thus, PF4 is a ligand for the integrin CR3, suggesting that many immune-modulating effects previously ascribed to PF4 were mediated by its interaction with CR3. PF4 directly binds to the aMI-domain, the major ligand-binding region, of CR3. Binding sites for aMI-domain were identified in two positively charged PF4 segments: Cysl2-Ser26 (CVKTTSQVRPRHITS, SEQ ID NO: 4) and Ala57-Ser70 (APLYKKIIKKLLES, SEQ ID NO: 5), which are fully exposed on the surface in either the monomer or tetramer aggregation states. The presence of two binding sites allows one site to bind the negatively charged bacterial surface while the other binds the macrophage receptor CR3. As such, PF4 is an opsonin. Fragments of PF4 include polypeptides comprising contiguous portions of PF4 that retain antimicrobial function. Thus, in some aspects, fragments of PF4 include the two binding sites to the aMI-domain of CR3.

[0039] As shown in the Examples, monomers and dimers of rPF4, rather than the trimer or tetramers of native PF4, exhibited phagocytosis-promoting activity of macrophages in response to a pathogen (FIG. 3D). Interestingly, PF4-N isolated from platelets exhibits some phagocytosis-promoting activity of macrophages, though at markedly lower levels than monomers or dimers of rPF4. As such, antimicrobial compositions comprising monomers and / or dimers of rPF4 and / or a variant or fragment thereof are described herein. In some embodiments, the aggregation state of the PF4 composition is at least 70% monomers and dimers, at least 75% monomers and dimers, at least 80% monomers and dimers, at least 85% monomers and dimers, at least 90% monomers and dimers, or at least 95% monomers and dimers. In some embodiments, the composition consists essentially of platelet factor 4 (PF4) and / or variant thereof in dimeric and monomeric aggregation states. Thus, in some embodiments, the composition does not comprise trimeric or a tetrameric aggregation states ofAttorney Docket No. 11157.215W0-PCTPF4 or variant thereof. In certain implementations, the antimicrobial compositions described herein are useful for the treatment of a microbial infection, for example, one caused by antibiotic-resistant bacteria.

[0040] FIGs. 4A and 4B indicate that recombinant PF4 predominantly having the dimeric aggregate state (rdPF4) enhances rPF4’s effect of enhancing phagocytosis. Accordingly, in some embodiments, the antimicrobial composition comprises at least 60% dimers of rPF4. In some embodiments, the composition comprises at least 70% dimers of rPF4, at least 75% dimeric of rPF4, at least 80% dimers of rPF4, or at least 90% dimers of rPF4. In some aspects, such a composition comprises at least 10% monomers of rPF4. In some embodiments, such a composition comprises at least 20% monomers of rPF4. The composition may further comprise pharmaceutically acceptable carriers, excipients, or diluents. For example, the antimicrobial composition consists of PF4 and / or variant thereof in dimeric aggregation states; optionally PF4 and / or variant thereof in monomeric aggregation states; and optionally a pharmaceutically acceptable carrier, excipient, or diluent. In some embodiments, the composition is formulated for systemic or local administration, including intravenous and intraperitoneal administration.

[0041] rPF4 and / or a variant or fragment thereof exhibit antimicrobial activity against Gramnegative bacteria and Gram-positive bacteria, even when they are antibiotic-resistant. In some embodiments, rPF4 enhances phagocytosis of a Gram-negative bacterial population selected from the Pseudomonas, Klebsiella, Acinetobacter, Enterobacter, Salmonella, and Escherichia families. In some embodiments, rPF4 enhances phagocytosis of a Gram-positive bacterial population selected from the Staphylococcus, Streptococcus, Enterococcus, Clostridium, and Listeria families. In some embodiments, the Gram-positive bacterial population comprises Staphylococcus aureus, Streptococcus pyogenes, and / or Streptococcus pneumoniae.

[0042] As used herein, when referring to PF4 and / or a variant or fragment thereof, the terms “monomer(s)”, “dimer(s)”, “trimer(s)”, and “tetramer(s)” are used interchangeably with “monomer aggregate / aggregation state(s)”, “dimer aggregate / aggregation state(s)”, “trimer aggregate / aggregation state(s)”, and “tetramer aggregate / aggregation state(s)”, respectively.

[0043] As used herein, the term “PF4” comprises native PF4 (used interchangeably with “PF-N”) and / or variants or fragments thereof and recombinant PF4 (used interchangeably with “rPF4”) and / or variants or fragments thereof.

[0044] Mutations in residues 15 and 16 of PF4 can increase binding to bacterial surfaces. Accordingly, in some embodiments, the variant of PF4 comprises a binding site for CR3 aMI-domain having the amino acid sequence CVKXXSQVRPRHITS (SEQ ID NO: 2), wherein X is not T or wherein X is R or a conservative substitution thereof. A mutation in residue 69 ofAttorney Docket No. 11157.215W0-PCTPF4 can also increase binding to the bacterial surface. Accordingly, in some embodiments, the variant of PF4 comprises a binding site for CR3 aMI-domain having the amino acid sequence APLYKKIIKKLLXS (SEQ ID NO: 3), wherein X is not E or wherein X is R or a conservative substitution thereof. In other embodiments, the variant of PF4 comprises at least one binding site for CR3 aMI-domain having the amino acid sequence APLYKKIIKKLLXiS (SEQ ID NO: 3) or CVKX2X3SQVRPRHITS (SEQ ID NO: 2), wherein: (1) Xi is not E or Xi is R or a conservative substitution thereof, (2)X2 is not T or X2 is R or a conservative substitution thereof, and / or (3) X3 is not T, or X3 is R or a conservative substitution thereof.

[0045] In some aspects, the monomers and dimers of PF4 are provided as a recombinant protein of PF4 (rPF4), namely that the recombinant protein has the amino acid sequence of a monomeric subunit of the native homotetrameric protein found in platelets but is not produced by a platelet cell. In some aspects, the cDNA sequence encoding is rPF4 has a sequence of GAAGCTGAAGAAGATGGGGACCTGCAGTGCCTGTGTGTGAAGACCACCTCCCAG GTCCGTCCCAGGCACATCACCAGCCTGGAGGTGATCAAGGCCGGACCCCACTGC CCCACTGCCCAACTGATAGCCACGCTGAAGAATGGAAGGAAAATTTGCTTGGAC CTGCAAGCCCCGCTGTACAAGAAAATAATTAAGAAACTTTTGGAGAGT (SEQ ID NO: 1). While the molecular weight and antigenic properties of the monomeric recombinant protein are similar to those of the subunit from the native protein, rPF4 differs in that it cannot assemble into tetramers and can only form dimers. These differences in molecular properties affect the antimicrobial activity of the two proteins, with the recombinant protein being significantly more active than the native version. The ease of purifying the recombinant protein, combined with its antibacterial properties and effectiveness against antibiotic-resistant bacteria, makes the protein a promising treatment for various bacterial infections, including sepsis. Accordingly, in some embodiments, the antimicrobial compositions comprising monomers and / or dimers of recombinant PF4. In other embodiments the antimicrobial compositions comprise monomers and / or dimers of recombinant PF4 or a variant thereof. In some embodiments, the variant of rPF4 comprises a binding site for CR3 aMI-domain having the amino acid sequence CVKXXSQVRPRHITS (SEQ ID NO: 2), wherein X is not T or wherein X is R or a conservative substitution thereof. In some embodiments, the variant of PF4 comprises a binding site for CR3 aMI-domain having the amino acid sequence APLYKKIIKKLLXS (SEQ ID NO: 3), wherein X is not E or wherein X is R or a conservative substitution thereof. In other embodiments, the variant of PF4 comprises at least one binding site for CR3 aMI-domain having the amino acid sequence APLYKKIIKKLLXiS (SEQ ID NO: 3) or CVKX2X3SQVRPRHITS (SEQ ID NO: 2), wherein Xi is not E, Xi is R or a conservativeAttorney Docket No. 11157.215W0-PCTsubstitution thereof, X2 is not T or X2 is R or a conservative substitution thereof, and / or X3 is not T or X3 is R or a conservative substitution thereof.

[0046] Also described herein are methods of treating a bacterial infection or methods of reducing the severity of a bacterial infection in a subject. In some aspects, the bacteria causing the bacterial infection is antibiotic-resistant. The methods comprise administering to a subject in need thereof the antimicrobial composition described above. In other implementations, the methods comprise administering PF4 and / or variant thereof in dimeric aggregation states to the subject. In some aspects, the PF4 in dimeric aggregation states administered is rPF4. In some embodiments, the method further comprises administering to the subject an antibiotic compound, a non-antibiotics antibacterial substance, or a glucocorticoid. Because PF4 or a variant thereof does not directly kill the bacteria, combination use with an agent that directly targets bacteria, like an antibiotic compound or a non-antibiotics antibacterial substance, could result in additive if not synergistic bactericidal effects. Thus, in some implementations, the antimicrobial composition is administered with at least one antibiotic selected from the group consisting of: ceftriaxone, levofloxacin and ampicillin. Also, in the treatment of sepsis, glucocorticoids are commonly used to prevent shock associated with sepsis. However, high levels of inflammatory cytokines in sepsis (a phenomenon also called “cytokine storm”) can result in systemic or tissues-specific corticosteroid resistance. Thus, in some embodiments, the described antimicrobial compositions further comprise at least one of a glucocorticoid (for example, hydrocortisone) and an antibiotic. In certain implementations, the method of treating a bacterial infection or method of reducing the severity of a bacterial infection in a subject consists essentially of administering PF4 and / or variant thereof in dimeric aggregation states to the subject. In other implementations, the method of treating a bacterial infection or method of reducing the severity of a bacterial infection in a subject consists essentially of administering PF4 and / or variant thereof in dimeric and monomeric aggregation states to the subject, wherein at least 70% of PF4 administered are in dimeric aggregation states, at least 75% of PF4 administered are in dimeric aggregation states, at least 80% of PF4 administered are in dimeric aggregation states, or at least 90% of PF4 administered are in dimeric aggregation states.

[0047] Accordingly, kits for clearance of a bacterial infection and for managing sepsis are additionally described. In one aspect, the kit for clearance of a bacterial infection comprises an antimicrobial composition described herein and a second antimicrobial agent selected from an antibiotic and a non-antibiotic antibacterial substance. In another aspect, the kit comprises PF4 and / or variant thereof in dimeric and monomeric aggregation states and a second antimicrobial agent selected from an antibiotic and a non-antibiotic antibacterial substance. The kits forAttorney Docket No. 11157.215W0-PCTmanaging sepsis comprises an antimicrobial composition described herein and at least one additional pharmaceutical agent selected from a glucocorticoid and antibiotic. In another aspect, the kit comprises PF4 and / or variant thereof in dimeric and monomeric aggregation states and at least one additional pharmaceutical agent selected from a glucocorticoid and antibiotics.

[0048] In some aspects, the antimicrobial compositions described above comprise pegylated PF4 or a variant thereof, including a fragment of PF4. In some aspects, the monomer or the dimer of PF4 or variant thereof is pegylated at the N-terminal of the PF4 or recombinant PF4 with a polyethylene glycol (PEG) chain of less than 10 kDa in weight. In certain implementations, the PF4 or variant thereof is pegylated with methoxy PEG propionaldehyde (mPEG). In particular embodiments, the molecular weight of the mPEG is 5 kDa and / or the PF4 or variant thereof is mono-pegylated. The antibiotic composition comprising pegylated PF4 or a variant thereof may exhibit (1) increased therapeutic potential, as longer circulation times can improve efficacy in treating bacterial infections; 2) reduced dosing frequency; and 3) minimized immunogenicity and decreased adverse immune responses thus improved safety for long-term use.

[0049] A method for monospecific pegylation of PF4 is further disclosed. The method comprises providing rPF4 and a PEG chain at a molar ratio of at no more than 10 moles of the PEG chain to 1 mole of rPF4 and combining the rPF4 and the PEG chain in a buffer with a pH of no higher than 6.0 to produce a pegylation reaction mixture. The rPF4 and PEG chain are then allowed to react in the buffer for 18-36 hours after which the monopegylated rPF4 is isolated from the pegylation reaction mixture.

[0050] In some aspects, the rPF4 and PEG chain are provided at a molar ratio of 3-10 moles of the PEG chain to 1 mole of rPF4, a molar ratio of 3-5 moles of the PEG chain to 1 mole of rPF4, or about 4 moles of the PEG chain to 1 mole of rPF4. In some aspects, the PEG chain has a molecular weight of less than 10 kDa. In certain embodiments, the molecular weight of PEG chain is about 5 kDa. In particular embodiments, the PEG chain is methoxy PEG propionaldehyde (mPEG).

[0051] In some aspects, the pH of the buffer is between 5.0 to 6.0. In some embodiments, the pH In some aspects, the PF4 is pegylated using aldehyde chemistry in a buffer comprising a sodium borohydride. In some embodiments, the sodium borohydride is sodium cyanoborohydride (NaCNBHs).Illustrative., Non-Limiting Examples in Accordance with Certain EmbodimentsAttorney Docket No. 11157.215W0-PCT

[0052] The disclosure is further illustrated by the following examples that should not be construed as limiting. The contents of all references, patents, and published patent applications cited throughout this application, as well as the Figures, are incorporated herein by reference in their entirety for all purposes.Example 1. Evaluation of recombinant PF4 isolation

[0053] Standardized preparations of rPF4 were developed using several biochemical and cellbased assays, including analyses by SDS-PAGE, Western blotting, size-exclusion chromatography, and flow-cytometry-based phagocytic assay with cultured mouse and human macrophages, and primary leukocytes.

[0054] rPF4 was generated using a pET-15b plasmid and purified by affinity chromatography using heparin-agarose as described in Lishko et al. (Lishko et al., “Leukocyte integrin Mac-1 (CDllb / CD18, alpha M beta 2, CR3) acts as a functional receptor for platelet factor 4.” Journal of Biological Chemistry. 2018;293(18):6869-6882.) and in Podolnikova et al. (Podolnikova et al., “Platelet factor 4 improves survival in a murine model of antibiotic-susceptible and methicillin-resistant S. aureus peritonitis.” Front Cell Infect Microbiol. 2023 Oct 4; 13: 1217103). As shown in FIG. 1A, rPF4 migrates as a single band in the 4-20% SDS-polyacrylamide TRIS-glycine buffer with a molecular weight of ~12 kDa. This molecular weight was confirmed by Western blotting with anti-PF4 polyclonal antibodies (FIG. 1C). Since small proteins exhibit atypical behavior in the TRIS-glycine buffer system, rPF4 was also analyzed using a TRIS-tricine buffer system, which is more amenable to small proteins and peptides. Even though the molecular weight of rPF4 was lower (~10 kDa) in this system, it was still higher than a theoretical 7.8 kDa expected for the PF4 monomer (FIG. IB). To determine the aggregation state of rPF4, its molecular weight was analyzed by size-exclusion chromatography using the BioSEC-3 (Agilent) column and the HPLC system. As shown in FIG. 2, rPF4 was eluted as a mixture of dimers and monomers (second panel from the top). The composition of the rPF4 mixture was 80% dimers and 20% monomers.

[0055] The activity of rPF4 was determined in a flow-cytometry-based phagocytic assay using pHrodo-labeled S. aureus bioparticles and a mouse macrophage cell line IC-21. As shown in FIGs. 3 A and 3D, rPF4 at 50 pg / ml increased phagocytosis by ~6 fold.

[0056] Since rPF4 was a mixture of dimers and monomers, the biochemical properties of the natural PF4 (PF4-N) isolated from human platelets, known as a tetramer, was characterized. PF4-N was isolated by affinity chromatography on heparin-agarose from outdated platelets as previously described and analyzed by SDS-PAGE, Western blotting, and size-exclusionAttorney Docket No. 11157.215W0-PCTchromatography. The molecular weight of PF4-N assessed by SDS-PAGE and Western blotting was similar to that of rPF4 (FIGs. 1A-1C). However, by size-exclusion chromatography, the elution profile of PF4-N agreed with the presence of trimers and tetramers, as determined for two separate preparations (FIG. 2, third and fourth panels).

[0057] Testing these preparations of PF4-N in phagocytic assays showed that they exhibited a markedly lower phagocytosis-promoting activity of pHrodo-labeled S. aureus particles by macrophages (FIGs. 3B-3D). Notably, the preparation enriched in trimers and tetramers was inactive. The increase in the concentration of PF4-N did not result in the augmentation of its effect on phagocytosis. Thus, the preparation containing only dimers and monomers of PF4 exhibits higher phagocytosis-promoting activity than the native tetrameric protein. In a mouse model of infectious peritonitis, rPF4 facilitated the clearance of both antibiotic-susceptible and methicillin-resistant Staphylococcus aureus (MRSA), thereby improving survival rates (FIGs.4A-4C).

[0058] Whether rPF4 is agnostic to pathogen type was also determined by assessing its effect on phagocytosis of Gram-negative encapsulated Klebsiella pneumoniae and its antibioticresistant variant. rPF4 enhances CR3-mediated phagocytosis of both live bacteria and heat-inactivated K. pneumoniae particles by various mouse and human macrophage cell lines, as well as primary neutrophils and macrophages (FIGs. 5A and 5B). rPF4 did not directly kill bacteria; instead, it acted as an opsonin by binding to the negatively charged bacterial capsule at high density, creating recognition sites for CR3 on leukocytes. A single dose of rPF4 injected into mice infected with different strains of K. pneumoniae significantly enhanced bacterial clearance from the lungs, liver, and peritoneum, and reduced bacteremia (FIG. 6A). Histological analyses showed that rdPF4 provided substantial protection against damage to lung and liver tissues caused by K. pneumoniae (FIGs. 6B-6D). Consistent with these findings, rPF4 treatment increased the survival rates of infected mice (FIG. 6E). These results show that rPF4 is effective against both Gram-negative and Gram-positive bacteria, suggesting a common mechanism where rPF4 targets the negatively charged bacterial capsule, thereby reducing its antiphagocytic properties.Example 2. Comparison with a commercially available rPF4

[0059] Recombinant PF4 (Catalog #550904) from BioLegend (San Diego, CA) was characterized using size-exclusion chromatography. Unlike native PF4, the rPF4 from BioLegend also lack tetrameric aggregation states. When compared with the rPF4 prepared as described in Example 1 (referred to hereinafter as “rdPF4”), BioLegend’s rPF4 has a more evenAttorney Docket No. 11157.215W0-PCTdistribution between the dimers and dimers (FIG. 7A). Specifically, rPF4 from BioLegend has 52% dimers and 48% monomers, while rdPF4 has predominantly in dimers (78% dimers and 22% monomers).

[0060] The difference in the distribution of monomers and dimers appeared to affect the rPF4’ s efficacy in enhancing phagocytosis. rPF4 from BioLegend promoted phagocytosis less effectively than rdPF4, but its activity was still significantly higher than in the absence of PF4 (FIG. 7B). Taken together with the results of FIG. 3D, a mixture of dimers and monomers (such rPF4 preparation) exhibited significantly greater phagocytosis-promoting activity compared to the native PF4 isolated from platelets, which is primarily in the tetrameric aggregation state.

[0061] Table 3 summarizes the comparison between rdPF4 and BioLegend’s rPF4.Table 3.Composition Phagocytosis, Tetramer Dimer Monomer fold increase rdPF4 0 78 22 5.22 ± 0.60 PF4-N-1 54 29 18 1.90 ± 0.80BioLegend’s rPF4 0 52 48 4.23 ± 0.10Example 3, Cytotoxicity of rPF4

[0062] Cultured IC-21 mouse macrophages, isolated mouse resident peritoneal leukocytes (macrophages + lymphocytes), and human U937 monocytic cells (5xl05 / ml) were loaded with calcein for 30 min at 37°C, washed in HBSS, and incubated with different concentrations of rPF4 and LL-37 for 30 min at 22°C. Cells were centrifuged, and calcein leakage from cells was assessed by measuring the fluorescence of the supernatant. The effects of LL-37 and rPF4 were compared side-by-side for each cell type. LL-37 has a cytotoxic effect on mammalian cells, and the level of calcein leakage caused by LL-37 treatment indicates cytotoxicity. As shown in FIG. 8, rdPF4 does not have a cytotoxic effect on mammalian cells.Example 4, Pegylation of PF4

[0063] While a single dose of rPF4 significantly improved bacterial clearance and survival rates, its effect can likely be improved by increasing the life-time in the circulation. The linear polymer polyethylene glycol (PEG) has extensively been used in the pharmaceutical industry to improve pharmacokinetic properties of protein and peptide drugs. The covalent conjugation of PEG molecules to protein and peptide therapeutics increases the life-time in blood by enhancing its stability and resistance to proteolytic enzymes. Thus, to increase the life-time ofAttorney Docket No. 11157.215W0-PCTrPF4, pegylated rPF4 was contemplate. However, the pegylation strategy must avoid random modification of the epsilon-amino group of multiple lysines that are required for rPF4 activity. The N-terminal part of rPF4 is not involved in its binding activity to the bacterial surface and CR3. Thus, a pegylation strategy involving modification of the N-terminus of rPF4 with methoxy-PEG derivative was developed. Furthermore, it is preferable that the pegylation reaction is a monopegylation reaction.a. Optimization of pegylation reaction conditions

[0064] Monospecific pegylation of proteins at the N-terminus can be influenced by various factors, for example, the selection of an appropriate PEG modifier, the pH, the molar ratio of PEG to protein, the molecular weight and molecular structure of PEG, and the time and temperature of the pegylation reaction. Accordingly, these reaction conditions were optimized through a series of experiments.

[0065] PEG modifier: For monospecific pegylation of rPF4, aldehyde chemistry with methoxy PEG propionaldehyde (mPEG) occurring in the presence of sodium borohydride (NaCNBHs) was selected.

[0066] pH: pH is a critical factor that can influence N-terminal pegylation. It is known that site-specific pegylation of proteins at the N-terminus requires slightly acidic pH conditions. This strategy is based on the fact that N-terminal alpha-amino groups in proteins have different pKa values compared to epsilon-amino groups in lysine residues. To optimize pH, the reaction was conducted at three pHs, 5.0, 5.5 and 6.0.

[0067] The molar ratio: Four molar ratios of mPEG to rPF4 were tested: 3:1, 4:1, 5:1 and 10:1.

[0068] MW and molecular chain structure of PEG: Although increasing the MW of PEG can extend the half-life of a drug, higher MWs or branched PEGs exhibit a stronger steric hindrance effect, which may mask the binding site for the receptor. Since rPF4 is a relatively small protein, two linear low-molecular weight PEGs with MW of 5 Da and 10 Da were selected for testing.

[0069] Time and temperature: All reactions were conducted for 24 hours at 22°C.b. Optimization results

[0070] The kinetics of the pegylation reaction were monitored by SDS-PAGE. In the initial analyses, molar ratio of PEG:rPF4 ranging from 3:1 to 5:1 produced lower quantities of multi -PEGylated products compared to the 10: 1 molar ratio. Thus, the molar ratio of 4: 1 was selected for subsequent analyses. The pH range of 5.0 to 6.0 did not affect the reaction. Pegylation of rPF4 with a 10 kDa mPEG at pH 5.0 resulted in the appearance of the mono-PEGylated productAttorney Docket No. 11157.215W0-PCTafter 4 hours of incubation followed by the emergence of the band corresponding to a bi-PEGylated product after 6 hours. The formation of both products increased after 24 hours. No products with a greater molecular weight were detected. The final mixture consisted of unmodified rPF4, mono-PEGylated and bi-PEGylated products with mono-PEGylated rPF4 being the predominant product (FIG. 9A). The components of the mixture were separated by size-exclusion chromatography (FIG. 9B) and mono-PEGylated rPF4 was tested for its activity in the standard phagocytic assay with IC-21 macrophages and pHrodo-labeled S. aureus bioparticles. The analysis demonstrated that the activity of mono-PEGylated rPF4 was significantly lower than that of the initial unmodified rPF4 (FIG. 9C), suggesting that the 10 EDa PEG may mask the binding site on PEGylated rPF4 for CR3 or reduce its binding to bacteria.c. Functional studies with pegylated rPF4

[0071] mPEG with a molecular weight of 5 kDa was reacted with rPF4 at the 4:1 molar ratio. The reaction was conducted at pH 5.0. SDS-PAGE analysis revealed the presence of only mono-PEGylated rPF4 after 4-6 hours with no band corresponding to a bi-PEGylated product (FIG. 10A). After 22 hours, most rPF4 had converted into mono-PEGylated rPF4 with only small amounts of the bi-PEGylated molecule present (FIG. 10A).

[0072] Mono-PEGylated rPF4 was separated from bi-PEGylated and unreacted molecules by cation exchange chromatography using a HiTrap SP HP column (FIG. 10B). SDS-PAGE analyses of the fractions showed the presence of mono-PEGylated rPF4 in peak 3 (FIG. 10C).Phagocytic assays demonstrated that mono-PEG-5K was active, though it retained 75 % activity compared to the unmodified protein (FIG. 10D). It is well known that PEGylation results in reduced bioactivity. However, the prolonged in vivo half-life of PEGylated proteins often compensates for the decrease in biologicals activity, leading to an overall increase in their therapeutic effects in vivo. Accordingly, it is expected that modest decrease in the phagocytosis-promoting activity of monoPEGylated PF4 will be compensated by its increased half-life (see, for example, P. Bailon, and W. Berthold. “Polyethylene glycol-conjugated pharmaceutical proteins.” Pharm. Sci. Tech. Today, 1998, 1:352-356.)

Claims

Attorney Docket No. 11157.215W0-PCTCLAIMSWhat is claimed:

1. A pharmaceutical composition for the treatment of a microbial infection comprising platelet factor 4 (PF4) and / or a variant thereof in dimeric and monomeric aggregation states.

2. A pharmaceutical composition for use in the treatment of an antibiotic-resistant microbial infection comprising platelet factor 4 (PF4)and / or variant thereof in dimeric and monomeric aggregation states.

3. The pharmaceutical composition of claim 1 or 2, wherein at least 60%, at least 70%, or at least 75% of the PF4 is in the dimeric aggregation state.

4. The pharmaceutical composition of claim 1 or 2, wherein the N-terminus of the PF4 and / or variant or fragment thereof is pegylated with a polyethylene glycol (PEG) chain of 10 kDa or less in weight.

5. The pharmaceutical composition of claim 4, wherein the PEG chain is a methoxy PEG propionaldehyde (mPEG).

6. The pharmaceutical composition of claim 5, wherein the molecular weight of the PEG chain is 5 kDa or less.

7. Recombinant PF4 (rPF4) or variant thereof for use in the treatment of a microbial infection, wherein the N-terminus of the rPF4 and / or variant or fragment thereof is pegylated with a polyethylene glycol (PEG) chain of 10 kDa or less in weight.

8. The rPF4 or variant thereof of claim 7, wherein the PEG chain is a methoxy PEG propionaldehyde (mPEG).

9. The rPF4 or variant thereof of claim 8, wherein the molecular weight of the PEG chain is 5 kDa or less.

10. Dimeric aggregation state of recombinant PF4 (rPF4) or variant thereof for use in the treatment of a microbial infection.

11. The rPF4 or variant thereof of any one of claims 7-10, wherein the rPF4 or variant thereof is expressed by a DNA sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 1.

12. Use of platelet factor 4 (PF4) and / or variant thereof in dimeric and monomeric aggregation states in the manufacture of an antimicrobial medicament.

13. The use of claim 12, wherein at least 60%, at least 70%, or at least 75% of the PF4 in the manufactured medicament is in the dimeric aggregation state.

14. Use of dimeric aggregation state of platelet factor 4 (PF4) and / or variant thereof in the manufacture of an antimicrobial medicament.Attorney Docket No. 11157.215W0-PCT15. A kit for clearance of a bacterial infection comprising:an antimicrobial composition of any one of claims 1-6; anda second antimicrobial agent selected from an antibiotic and a non-antibiotic antibacterial substance.

16. A kit for clearance of a bacterial infection comprising:platelet factor 4 (PF4) and / or variant thereof in dimeric and monomeric aggregation states; anda second antimicrobial agent selected from an antibiotic and a non-antibiotic antibacterial substance.

17. A kit for management of sepsis comprising:platelet factor 4 (PF4) and / or variant thereof in dimeric and monomeric aggregation states; anda glucocorticoid.

18. A method of inducing phagocytosis of a bacterium in a subject comprising administering platelet factor 4 (PF4) and / or variant thereof in dimeric and monomeric aggregation states to the subject.

19. A method of reducing a bacterial population in a subject comprising administering platelet factor 4 (PF4) and / or variant thereof in dimeric and monomeric aggregation states to the subject.

20. The method of claim 19, wherein the bacterial population comprises antibiotic-resistant bacteria.

21. The method of any one of claims 18-20, wherein the PF4 and / or variant thereof in dimeric and monomeric aggregation states is recombinant PF4.

22. The method of any one of claims 18-20, further comprising administering to the subject an antibiotic or a non-antibiotic antibacterial substance.

23. A method of treating or reducing severity of a bacterial infection in a subject in need thereof, the method comprising administering platelet factor 4 (PF4) and / or variant thereof in dimeric and monomeric aggregation states to the subject.

24. The method of claim 23, further comprising administering to the subject an antibiotic or a non-antibiotic antibacterial substance.

25. The method of claim 23 or 24, further comprising administering to the subject a glucocorticoid.

26. The method of claim 25, wherein the bacterial infection has resulted in sepsis in the subject.Attorney Docket No. 11157.215W0-PCT27. The method of claim 23, wherein the bacterial infection is caused by antibiotic-resistant bacteria.

28. A method for monospecific pegylation of platelet factor 4 (PF4) comprising:providing a recombinant PF4 (rPF4) and a polyethylene glycol (PEG) chain at a molar ratio of at no more than 10 moles of the PEG chain to 1 mole of rPF4, wherein the PEG chain has a molecular weight of less than 10 kDa;combining the rPF4 and the PEG chain in a buffer with a pH of no higher than 6.0 to produce a pegylation reaction mixture;allowing the rPF4 and PEG chain to react in the buffer for 18-36 hours; and isolating monopegylated rPF4 from the pegylation reaction mixture.

29. The method of claim 28, wherein the rPF4 and PEG chain are provided at a molar ratio of 3-10 moles of the PEG chain to 1 mole of rPF4, 3-5 moles of the PEG chain to 1 mole of rPF4, or about 4 moles of the PEG chain to 1 mole of rPF4.

30. The method of claim 28 or 29, wherein the PF4 is pegylated using aldehyde chemistry in a buffer comprising a sodium borohydride.

31. The method of claim 30, wherein the sodium borohydride has a molecular formula of NaCNBH3.

32. The method of claim 28 or 29, wherein the PEG chain is methoxy PEG propionaldehyde (mPEG).

33. The method of claim 32, wherein the molecular weight of PEG chain is about 5 kDa.